Given the relationship between allergic rhinitis (AR) and asthma, it can be hypothesized that
reducing inflammation in the upper airway with intranasal corticosteroid (INCS) medications …

Objectives To address concerns related to the safety profile of both Food and Drug
Administration (FDA)–approved and non-FDA-approved intranasal corticosteroid (INCS) use …

Background The efficacy of topical corticosteroids is limited in chronic rhinosinusitis (CRS)
due to rapid clearance from the nasal cavity and insufficient drug delivery to inflamed …

Intranasal corticosteroids (INSs) are the most efficacious medication for the treatment of
allergic rhinitis. In 2006, the Joint Task Force of the American College of Allergy, Asthma …

Background Non‐allergic rhinitis is defined as dysfunction and non‐infectious inflammation
of the nasal mucosa that is caused by provoking agents other than allergens or microbes. It …

Introduction Allergic rhinitis (AR) is a common chronic inflammatory disease of the nasal
mucosa, affecting about 10–40% of children worldwide. Intranasal corticosteroids (INCSs) …

Objectives: The knowledge gap and attitude of allergic rhinitis (AR) patients using intranasal
corticosteroid (INCS) led to the poor outcome of their disease. We aimed to develop and …

Because of their efficacy, intranasal corticosteroids (INCS) remain the cornerstone in the
treatment of upper airway diseases. Although INCS are extremely efficacious, local and …

Given that intranasal corticosteroids (INCs) are widely considered first-line therapies for
treatment of rhinitis, it is important for the clinician to be comfortable with the side-effect …

Background Concurrent use of intranasal corticosteroids (INCSs) and inhaled
corticosteroids (ICSs) is indicated for patients who are comorbid for asthma and allergic …